
Trump's Rescheduling Order May Pave Way for D.C. Cannabis Sales
Federal reclassification could end D.C.'s long wait for legal sales
President Trump's executive order rescheduling marijuana could finally enable Washington D.C. to launch recreational cannabis sales, resolving a decade-long stalemate created by congressional interference.
D.C. voters approved recreational marijuana in 2014, but Congress blocked the district from implementing a regulated retail market using its authority over D.C.'s budget and laws.
If cannabis moves from Schedule I to Schedule III, some legal experts believe the congressional restrictions would no longer apply.
D.C.'s Unique Situation
Unlike states, which have sovereignty over internal policies, Washington D.C. operates under congressional oversight. Congress can block D.C. laws, control its budget, and interfere in local governance.
After D.C. voters approved Initiative 71 legalizing recreational cannabis possession and home cultivation, Congress inserted budget riders prohibiting the district from spending money to implement a regulatory framework for sales.
This created a legal grey area: adults can possess and grow cannabis, but there's no legal way to purchase it. "Gift economies" emerged where consumers paid for items like stickers or t-shirts and received cannabis as a free "gift"—a workaround that operates in legal ambiguity.
How Rescheduling Might Help
The congressional budget restrictions specifically referenced Schedule I substances. If cannabis moves to Schedule III, the legal basis for the restrictions could disappear.
D.C. officials have a regulatory framework ready to implement once barriers are removed. The district could potentially launch licensed sales relatively quickly compared to states building programs from scratch.
D.C.'s market would be modest in size given its small population, but it could generate significant tax revenue for the district and create a legally compliant alternative to the current grey market.
Remaining Obstacles
Congressional opponents of D.C. cannabis sales could potentially insert new restrictions based on Schedule III status, though the political dynamics might be different than with Schedule I.
And rescheduling itself isn't final—the DEA is still reviewing public comments on the proposed change. Timeline for implementation remains uncertain.
Impact if Sales Launch
Licensed D.C. cannabis sales would:
- Generate tax revenue for the district
- Create regulated, tested products replacing grey market alternatives
- Establish jobs in cultivation, processing, testing, and retail
- Provide a model for other federally administered jurisdictions
The district's central location and transient population (including tourists and commuters from Maryland and Virginia) could make the market larger than raw population suggests.
This article is based on original reporting by Marijuana Moment.
Original Source
This article is based on reporting from Marijuana Moment.
Read the original articleOriginal title: "Trump’s Marijuana Rescheduling Order Could Let Washington, D.C. Finally Legalize Recreational Sales"
Related Topics
Related Stories
LegislationMassachusetts Halts Cultivation Licenses as Prices Drop to $14/Eighth
Massachusetts Cannabis Control Commission approved a four-month freeze on new cultivation licenses starting June 16, responding to oversupply that's pushed retail prices down to $14 per eighth-ounce.
LegislationTrump Executive Order Fast-Tracks Psychedelic Research Access
Trump's executive order directs federal agencies to fast-track psychedelic research and clinical access programs for mental health treatment, though implementation faces similar regulatory hurdles that have complicated cannabis reform.
LegislationColorado Regulators Target Illegal Hemp Product Sales
Colorado's Marijuana Enforcement Division announced Monday it will crack down on companies selling intoxicating hemp products outside the regulated cannabis system, citing public safety and market integrity concerns.
More from David Okonkwo
View all articles
Trump Executive Order Fast-Tracks Psychedelic Research Access

Rhode Island Cannabis Officials Challenge Court Block on Licenses

FDA Signals Hemp CBD Enforcement Shift, But Industry Wants Legislation

